INTS Stock Analysis: Buy, Sell, or Hold?
INTS - Intensity Therapeutics, Inc. Common stock
$4.92
0.14 (2.93%)
▲
5d:
+8.85%
30d:
+31.55%
90d:
-10.55%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When INTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: INTS is 8.4% above its trading range ($4.54). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: INTS is 8.4% above its trading range ($4.54). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: INTS is currently trading at $4.92, which is considered extended relative to its 30-day fair value range of $3.70 to $4.54.
Technical Outlook: Technically, INTS is in a downtrend. The price is approaching resistance at $4.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $24.80 (+404.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INTS is in a downtrend. The price is approaching resistance at $4.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $24.80 (+404.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.70 -
$4.54
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range (+8.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 404.1% below Wall St target ($24.80)
Trading Range Analysis
30-Day Trading Range
$3.70 -
$4.54
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.51
Resistance Level
$4.66
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.82
Wall Street Target
$24.80
(+404.1%)
Share & Embed Analysis
Last updated: July 14, 2026 9:01 AM ET
Data refreshes hourly during market hours. Next update: 10:01 AM
Data refreshes hourly during market hours. Next update: 10:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
